VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 1 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2023. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $2,003,000 | -45.6% | 86,200 | -62.7% | 0.16% | -54.6% |
| Q1 2018 | $3,682,000 | +59.9% | 231,276 | +108.8% | 0.35% | +13.7% |
| Q4 2017 | $2,302,000 | +99.5% | 110,787 | +37.6% | 0.31% | +46.4% |
| Q3 2017 | $1,154,000 | -60.7% | 80,510 | -52.6% | 0.21% | -51.7% |
| Q2 2017 | $2,939,000 | +796.0% | 169,892 | +472.1% | 0.43% | +312.4% |
| Q1 2017 | $328,000 | -59.5% | 29,697 | -10.0% | 0.10% | +12.9% |
| Q3 2016 | $810,000 | -74.3% | 33,000 | -78.9% | 0.09% | -33.1% |
| Q2 2016 | $3,148,000 | -49.8% | 156,289 | +141.4% | 0.14% | -43.5% |
| Q1 2016 | $6,273,000 | -16.3% | 64,751 | +8685.8% | 0.25% | +5.1% |
| Q4 2015 | $7,492,000 | +414.6% | 737 | -88.8% | 0.23% | +766.7% |
| Q2 2015 | $1,456,000 | +1.8% | 6,553 | -9.0% | 0.03% | -41.3% |
| Q1 2015 | $1,430,000 | +81.5% | 7,200 | +30.9% | 0.05% | +142.1% |
| Q4 2014 | $788,000 | -16.3% | 5,500 | -23.4% | 0.02% | -36.7% |
| Q3 2014 | $942,000 | – | 7,179 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,373,210 | $47,796,000 | 39.06% |
| Claren Road Asset Management, LLC | 77,527 | $1,561,000 | 18.46% |
| Okumus Fund Management Ltd. | 4,242,012 | $85,434,000 | 14.79% |
| Chou Associates Management | 1,446,843 | $29,139,000 | 11.12% |
| FARLEY CAPITAL L.P. | 307,458 | $6,192,000 | 9.65% |
| HAP Trading, LLC | 3,129,700 | $112,397,000 | 6.58% |
| Pershing Square Capital Management | 21,591,122 | $434,845,000 | 5.79% |
| NORTH TIDE CAPITAL, LLC | 2,500,000 | $50,350,000 | 5.61% |
| Convector Capital Management, LP | 192,000 | $3,867,000 | 5.34% |
| Nebula Capital Management, LP | 31,770 | $640,000 | 5.07% |